Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.
about
Utility of a simple prognostic stratification based on platelet counts and serum albumin levels in elderly patients with diffuse large B cell lymphoma.High-Grade Transformation in a Splenic Marginal Zone Lymphoma with a Cerebral Manifestation.Leukaemic subtype of marginal zone lymphoma: a presentation of three cases and literature review.Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing.Synchronous rectal adenocarcinoma and splenic marginal zone lymphoma.Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy.Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria.Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disordersSplenectomy with chemotherapy vs surgery alone as initial treatment for splenic marginal zone lymphomaA phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas.Treatment of splenic marginal zone lymphoma: should splenectomy be abandoned?Splenic marginal zone lymphoma: disease features and management.Tissue proteomics of splenic marginal zone lymphoma.Splenic marginal zone lymphoma: a literature review of diagnostic and therapeutic challenges.Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly Patients.Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology.Histologic transformation in marginal zone lymphomas†.Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone lymphoma: a Fondazione Italiana Linfomi phase II study.Splenic Marginal Zone Lymphoma and Concurrent Membranoproliferative Glomerulonephritis With IgMKappa Deposits in a HCV-Seropositive PatientLong-term follow-up analysis of 100 patients with splenic marginal zone lymphoma treated with splenectomy as first-line treatment.The prognostic impact of clinical and molecular features in hairy cell leukaemia variant and splenic marginal zone lymphoma.Survival of patients with marginal zone lymphoma: analysis of the Surveillance, Epidemiology, and End Results database.Comparative outcomes of rituximab-based systemic therapy and splenectomy in splenic marginal zone lymphoma.ESMO Consensus conferences: guidelines on malignant lymphoma. part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma.Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.Important Diagnostic Clues for Diagnosing Splenic Marginal Zone Lymphoma in Absence of Splenic Histology.Distinct clinical characteristics draw a new prognostic model for splenic marginal zone lymphoma in HBV high prevalent region.Unusual Course of Splenic Marginal Zone Lymphoma.Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients.Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.A variant chronic B-cell lymphoma characterized by villous cells with novel immunophenotypic and cytogenetic profiles.Management of relapsed/refractory marginal zone lymphoma: focus on ibrutinib.Outcomes in splenic marginal zone lymphoma: analysis of 107 patients treated in British Columbia.
P2860
Q33435420-FC3BC659-68DE-4785-B027-6B39B8EFE5ADQ33442303-5E9F4019-4CF2-49C9-94FD-99DE9B48C3D8Q35782582-2696C263-2A3B-4A56-B129-9DCD898315E3Q35812737-72161343-AD86-44BD-A170-E8FA0DA348ACQ36581506-82D2086C-69DD-43EA-AD04-8A4AE1B71E3CQ36630461-7047E29E-4771-4FB4-9FB8-D63CBC2BAEEBQ37038412-2929563D-3FB4-4E56-9AA8-90F2481CFE42Q37171576-1C2EA5B0-A7A0-4D48-B4D0-747FEFF176AFQ37318560-9D558332-E8D1-4A99-9E75-0E00056AFC04Q37364653-BD6F5841-669A-47F9-AD8E-178D7A287D01Q38139569-952EAFD7-2A58-49C7-8312-AEFC36549FE8Q38156238-B050207F-0341-40E2-9E45-EFAC3A5CCFC4Q38413335-CDC227C6-5526-4FB4-8270-654F964D1582Q39347902-4B4FF988-473F-4BEF-843A-A8BABCF60C90Q39603542-183DE611-90D2-4178-96CA-8098C0D1F866Q40039607-02AA46D9-FB29-43CC-918E-6EF371092F0FQ41326723-978FCEAB-1059-428B-B8B6-1DA4B4562DA9Q41407104-48B646BF-85ED-4EC7-A2D7-31511FCB9DCFQ41475888-9B2B83FF-606E-412F-8D72-4EE7BF73880FQ42256967-6A530B24-5ABD-4D11-B8FB-B4BE6DFC4B47Q43854217-39AD57F3-F02B-428D-8B5C-E94BCE0B86E1Q44223923-57C6F2E6-7ADC-48B1-BB9A-EFEC3B745985Q44628624-DDDBC089-66DC-4956-ACB9-77FAF39880C4Q45124918-75AD1F58-F3CC-4E01-A74C-7E5EC59019F7Q46586197-14CA687C-F86D-466E-8FEA-E5DFEA4DBF72Q47121365-D342D634-5BA9-46BE-A505-001EDD3AA858Q47123855-D607BAED-06AE-4031-8A80-578412D1485DQ47153921-E850B67E-7B1F-4CAC-A5BC-810F18E43747Q47449201-27E3D876-9738-4F64-929E-5A33293DBFCAQ48331134-82E45894-EDA4-4D7A-B100-E87A7B516BDEQ50951617-870270F6-8A56-4B65-B6CF-FAEBF5EEA5FFQ52599792-20CD1D69-2252-4D14-BE74-A448E1B29D74Q53550375-C9E6952F-7102-4CA6-83E0-4E98F14FFAF4
P2860
Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մարտին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Prognostic features of splenic ...... tes: a report on 129 patients.
@ast
Prognostic features of splenic ...... tes: a report on 129 patients.
@en
type
label
Prognostic features of splenic ...... tes: a report on 129 patients.
@ast
Prognostic features of splenic ...... tes: a report on 129 patients.
@en
prefLabel
Prognostic features of splenic ...... tes: a report on 129 patients.
@ast
Prognostic features of splenic ...... tes: a report on 129 patients.
@en
P2093
P2860
P50
P1476
Prognostic features of splenic ...... tes: a report on 129 patients.
@en
P2093
Andrew C Wotherspoon
G John Swansbury
Nilima Parry-Jones
P2860
P304
P356
10.1046/J.1365-2141.2003.04165.X
P407
P577
2003-03-01T00:00:00Z